- Home
- TVGN vs ELDN Comparison
TVGN vs ELDN Comparison
Compare TVGN & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- ELDN
- Stock Information
- Founded
- TVGN 2020
- ELDN 2004
- Country
- TVGN United States
- ELDN United States
- Employees
- TVGN N/A
- ELDN N/A
- Industry
- TVGN Blank Checks
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- ELDN Health Care
- Exchange
- TVGN Nasdaq
- ELDN Nasdaq
- Market Cap
- TVGN 222.3M
- ELDN 232.4M
- IPO Year
- TVGN N/A
- ELDN N/A
- Fundamental
- Price
- TVGN $1.20
- ELDN $3.35
- Analyst Decision
- TVGN Strong Buy
- ELDN Strong Buy
- Analyst Count
- TVGN 1
- ELDN 1
- Target Price
- TVGN $10.00
- ELDN $16.00
- AVG Volume (30 Days)
- TVGN 515.9K
- ELDN 254.0K
- Earning Date
- TVGN 04-08-2025
- ELDN 03-20-2025
- Dividend Yield
- TVGN N/A
- ELDN N/A
- EPS Growth
- TVGN N/A
- ELDN N/A
- EPS
- TVGN N/A
- ELDN N/A
- Revenue
- TVGN N/A
- ELDN N/A
- Revenue This Year
- TVGN N/A
- ELDN N/A
- Revenue Next Year
- TVGN N/A
- ELDN N/A
- P/E Ratio
- TVGN N/A
- ELDN N/A
- Revenue Growth
- TVGN N/A
- ELDN N/A
- 52 Week Low
- TVGN $0.26
- ELDN $1.52
- 52 Week High
- TVGN $4.78
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- TVGN 48.29
- ELDN 33.23
- Support Level
- TVGN $1.13
- ELDN $3.22
- Resistance Level
- TVGN $1.26
- ELDN $3.63
- Average True Range (ATR)
- TVGN 0.07
- ELDN 0.19
- MACD
- TVGN 0.02
- ELDN -0.00
- Stochastic Oscillator
- TVGN 75.00
- ELDN 21.67
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.